Featured Research

from universities, journals, and other organizations

UNC Researchers Testing First In New Class Of AIDS Drugs

Date:
January 29, 1999
Source:
University Of North Carolina At Chapel Hill
Summary:
AIDS investigators at the University of North Carolina at Chapel Hill are testing the first of a new class of drugs that attacks HIV before it enters the cell and may prove effective for patients with drug-resistant HIV.

CHAPEL HILL, N.C. -- AIDS investigators at the University of North Carolina at Chapel Hill are testing the first of a new class of drugs that attacks HIV before it enters the cell and may prove effective for patients with drug-resistant HIV.

The fusion inhibitor, known as T-20, prevents HIV from fusing with the cell surface membrane. Thus, T-20 attacks HIV in an entirely different way than the most potent HIV agents now in use.

"HIV resistant to the currently available medications would not be expected to be resistant to this drug because of its unique action," says Dr. Joseph Eron, associate professor of medicine at the UNC-CH School of Medicine.

On Feb. 4, Eron will present detailed findings of the study at the Sixth Conference on Retroviruses and Opportunistic Infections in Chicago.

Eron is a principal investigator for this multi-center study begun in August and sponsored by Durham-based Trimeris, Inc., maker of T-20. He says the results are impressive, "particularly when one considers the population that enrolled in this clinical trial is extremely difficult to treat."

The infectious disease specialist notes that the average number of anti-HIV medications taken by the 78 HIV-infected patients prior to the Trimeris Phase II Clinical Trial was nine. None of the agents, including an average of three protease inhibitors per patient, had proven effective in these patients over the long-term. Additionally daunting was the patients' very high average baseline viral load -- the concentration of HIV particles per milliliter of blood. But according to Eron, patients in the new trial taking higher T-20 doses showed up to 90 percent reductions in viral load without major side effects.

In the trial, T-20 was given for 28 days either by continuous subcutaneous infusion or simply by injecting it subcutaneously (much like insulin is administered in diabetes). T-20 was also given either as part of an anti-retroviral drug "cocktail" or as the sole drug.

Eron says the new results definitively show that injection can be an alternative to infusion. Targeted blood levels of T-20 were achieved both through infusion and with twice-daily injections.

"This finding is important because twice-daily injection is far more convenient for patients than a continuous subcutaneous infusion pump," Eron explains.

"I think the study is extremely important because it is a clear demonstration of anti-retroviral effects with an agent that is completely novel, one that works by a different mechanism of action than currently available therapies," Eron says.

Results of this and subsequent T-20 investigations by Trimeris will be aimed at meeting rigorous Food and Drug Administration scrutiny to obtain approval for the drug.

"This particular trial was aimed at finding the correct dose and to show 'proof of principle' that the drug could be administered in a relatively convenient way," Eron says. "The trial lets me and others test a new drug on HIV patients who have failed lots of drugs and provides important information that will allow us to go on and study T-20 in combination with other HIV medications for longer durations."


Story Source:

The above story is based on materials provided by University Of North Carolina At Chapel Hill. Note: Materials may be edited for content and length.


Cite This Page:

University Of North Carolina At Chapel Hill. "UNC Researchers Testing First In New Class Of AIDS Drugs." ScienceDaily. ScienceDaily, 29 January 1999. <www.sciencedaily.com/releases/1999/01/990129074334.htm>.
University Of North Carolina At Chapel Hill. (1999, January 29). UNC Researchers Testing First In New Class Of AIDS Drugs. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/1999/01/990129074334.htm
University Of North Carolina At Chapel Hill. "UNC Researchers Testing First In New Class Of AIDS Drugs." ScienceDaily. www.sciencedaily.com/releases/1999/01/990129074334.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com
How The 'Angelina Jolie Effect' Increased Cancer Screenings

How The 'Angelina Jolie Effect' Increased Cancer Screenings

Newsy (Sep. 19, 2014) Angelina's Jolie's decision to undergo a preventative mastectomy in 2013 inspired many women to seek early screenings for the disease. Video provided by Newsy
Powered by NewsLook.com
The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins